Blocking common gateway to inflammation suppresses cancer

	Tweet

There is an intimate and complex relationship between inflammation and cancer; and it is well established that tumors secrete many different chemicals that attract host cells which drive inflammation and help to support tumor growth. Now, a new study published by Cell Press in the June issue of the journal Cancer Cell identifies a single protein that is required for trafficking of immune cells involved in inflammation. The research opens up new avenues for therapeutics that can indirectly suppress malignancy by disrupting the inflammatory response.

“Tumors induce inflammatory responses that stimulate tumor survival and progression. Therefore, targeting tumor inflammation could provide substantial therapeutic benefit to most, if not all, cancer patients,” says senior study author, Dr. Judith A. Varner from the University of California, San Diego. “However, effective suppression of tumor inflammation requires identification and targeting of mechanisms that are common to the many diverse inflammatory pathways that are activated during tumor growth.”

In their study, Dr. Varner and colleagues investigated the mechanisms that control tumor growth and inflammation by looking at molecular signals that are commonly activated by multiple diverse tumor-derived chemical signals. The researchers made the unexpected discovery that a single enzyme called PI3Kinase gamma served as a convergent point for a wide range of signaling pathways that controlled both tumor inflammation and progression.

A variety of experimental approaches with mouse and human cells demonstrated that disrupting PI3Kinase gamma prevented invasion of inflammatory cells into the tumor. Tumors developed more slowly and metastasis was suppressed in mice lacking PI3Kinase gamma even though cancer cells did not express PI3Kinase gamma and inhibitors had no direct effect on the tumor cells. The PI3Kinase gamma inhibitors indirectly interfered with the progression of cancer by preventing inflammation. Importantly, because the inhibitors do not directly influence tumor cells, it is not likely that they will develop resistance to PI3Kinase gamma inhibitors.

“Our studies show that PI3Kinase gamma is an excellent target for cancer therapeutics, as this enzyme is primarily expressed in specific immune cells and is a gatekeeper of tumor inflammation and tumor progression,” concludes Dr. Varner. “We found that PI3Kinase gamma inhibitors strongly suppressed tumor growth and progression in mice without apparent side effects. Thus, selective inhibitors of PI3Kinase gamma could serve as relatively nontoxic therapeutics to suppress tumor malignancy by blocking diverse pathways promoting tumor inflammation.”

###

Contact: Elisabeth (Lisa) Lyons

617-386-2121
Cell Press

RELATED STORIES:
Low vitamin D tied to cancer risk in men   Cancer gene therapy from camels   Disabling Skp2 Gene Helps Shut Down Cancer Growth   Ten Minutes That Could Save Your Life   Algorithm Ranks Genes’ Likelihood to Contribute to Cancer   Chemical in red wine, fruits and vegetables stops cancer, heart disease, depending on the dose   Targeting key proteins of carcinogenesis   Exercise Can Reduce Side Effects of Cancer Treatment   Targeting cholesterol may help slow glioblastoma   Computer-aided mammography improves tumor detection   Mistletoe as Cancer Treatment: Review Calls Evidence Weak   Personalized medicine helps cancer patients survive   Errors in cancer diagnosis common, often harmful   New Research Suggests Ways to Improve Cancer Therapy   Diet and cancer prevention: New evidence for the protective effects of fruits and veggies   Internet Research Builds Cancer Patients’ Confidence   Scientists Identify Order of Mutations that Lead to Cancer   Insight: Cancer in Africa: Fighting a nameless enemy   Duke team finds new clues to how cancer spreads   Lance Armstrong: Cancer a global problem   New target for cancer therapy identified by Australian researchers   Tumor mechanism identified

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]